Chesley Chen’s Post

🎷 What is the best start of the day? Chating with BioTech startup companies about protection of intellectual property! Thank you for having me StartBIO! 🙏 Few takeaways that are important for young companies: 🎯 decide and agree on the ownership of your IP rights as early as possible; 🎯 carefully analyze the agreement that you sign in relation to your studies, work or joint activities that relate to creating IP; 🎯 do not be afraid to negotiate with universities on the transfer or division of your IP rights; 🎯 the structure and ownership of your IP rights is the main thing that the future investor will look into - put your attention here. #iptips

Come have a chat with me about Quality and Regulatory too find a solution to help your organization!

🤔 Curious about 𝐨𝟐𝐡 𝐤𝐢𝐜𝐤𝐬𝐭𝐚𝐫𝐭𝐞𝐫 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐨𝐧…? Here’s the answers…✅ As the o2h kickstarter 5.0 is 𝐋𝐢𝐯𝐞 𝐍𝐨𝐰, we are pleased to announce that we have started receiving applications from 𝐔𝐒𝐀-𝐛𝐚𝐬𝐞𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐬𝐭𝐚𝐫𝐭-𝐮𝐩𝐬. The competition is closing soon. We have compiled a set of informative questions, i.e., 𝐅𝐫𝐞𝐪𝐮𝐞𝐧𝐭𝐥𝐲 𝐀𝐬𝐤𝐞𝐝 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 (𝐅𝐀𝐐𝐬), to assist you in gaining a deeper insight that you need about the competition. Please check out the below post and if you still have any queries, write us at [email protected] or visit - https://lnkd.in/dR8mbaPF #o2hkickstarter #seedingnewideas #o2hcollaborativeinnovation #unitedstates #nurturing #earlystage #biotech #lifescience #chemistryCRO #drugdiscovery #chemistry #research #faq

Scigilian is live at BioIT World 2024. Stop by booth 512 to learn how we can help optimize your lab operations. 🔬🦠#biotech #drugdiscovery #Scigilian

Of course many Enzyme Development projects fail. Here’s why: Most often than not, biocatalysis projects are pursued without any clear idea of the chances of success. For example: let’s say you have an enzyme development portfolio. You have to decide the next project to invest in, discarding other options from your portfolio. After spending weeks analyzing and defining priorities…you’ll allocate your resources on a project that will take several months and a considerable investment -risking company time and money- only to end up with poor results... …But what if that project just wasn’t the right option to begin with? You have now invested (precious) time and money in something that was meant to fail, while missing better opportunities from your portfolio. Just like you wouldn’t buy a sofa without checking first if it will fit in your living room, when it comes to enzyme development, there are certain specifics worth looking into before betting on a specific option. At @ ZYMVOL we’ve been helping our clients make better decisions in regards to their biocatalysis portfolio through #Zymplifier. Whether to assess the viability of potential routes or enhance enzyme performance, Zymplifier provides clear, data-driven guidance so you can invest only in what is most likely to succeed. What do you think? Can we help spread the application of biocatalysis by making it easier to implement (and succeed)? We believe so! Have a look at how 👇

SFBN Feed: Once hot to go public, life sciences companies in cash crunch now look at going private https://lnkd.in/gncNVmqv As public markets have slowed for biotech companies, including some that went public as generalist investors pumped money into the sector only two or three years ago, a handful are looking at going private. Click [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

So many biocatalysis projects end up failing because they were just not meant to be. When it comes to enzyme development, it’s hard to make the right decision without having clarity on the chances of success. Specially, with no reliable data. In the last few months, at ZYMVOL we’ve been envisioning the way to use our prediciting capabilities to solve this issue. And finally, today, we’re presenting #Zymplifier. Zymplifier is our data-driven approach to help all those innovators in the field of green chemistry find out the most promising opportunities in their enzyme development portfolio. Have a look at Zymplifier and start betting on what is most likely to succeed. 👉 https://lnkd.in/d4ACXiQP

  Last week, Jerry N Duff visited St. Louis for the US Biostimulants Summit and attended Keith Matthews's panel discussion on "Policy and Regulations Shaping the US Biostimulants Industry." During the Q&A two points were emphasized: 1) Startup companies are encouraged to address regulatory strategy early in the product development process to identify the pathway to product registrations; and, 2) Business strategy must be considered as well in order to coordinate registration pathways in other priority countries. Also recommended are pre-meetings with EPA and state regulatory bodies to help with direction for the registration process, including pitfalls to avoid. At AgriThority® we emphasize these points with our clients as we work to move new #biostimulant products and #technologies to market.    

Extremely topical #webinar today from Inpart ahead of #BIO2024 with helpful insights from J&J, especially on how #biotechs can improve both their outreach to and #partnering meetings with prospective #pharma #licensing partners. A few key points: 1. Focus on the science in your request for the meeting. 2. Clearly articulate how your science is novel and transformative, and the problem you're trying to solve. 3. Find a partner that shares your values. Look for a cultural fit that encourages a meaningful and long-term partnership.

#BioEurope Spring 2024 kicked off its three-day event yesterday, and our own Matthieu Coutet joined industry experts Lilian Alcaraz , Stephanie Marrus and Daniel Chancellor during the first session of Day 1, for a compelling discussion on 'company creation in the current biotech market.' Looking forward to more insightful conversations and connecting with investors, peers, partners, and friends throughout the event. If you're attending, do reach out. #BIOEuropeSpring #Biotech #lifesciences